Last $6.28 USD
Change Today -0.17 / -2.64%
Volume 20.3K
FATE On Other Exchanges
As of 8:10 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

fate therapeutics inc (FATE) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/26/14 - $13.55
52 Week Low
11/11/13 - $4.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for FATE THERAPEUTICS INC (FATE)

Related News

No related news articles were found.

fate therapeutics inc (FATE) Related Businessweek News

No Related Businessweek News Found

fate therapeutics inc (FATE) Details

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops pharmacologic modulators of adult stem cells to treat orphan diseases. Its hematopoietic stem cell (HSC) modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, which are adult stem cells that regenerate various types of blood cells throughout a person’s lifespan; and satellite cell modulation platform focuses on the in vivo pharmacologic activation of satellite stem cells that are adult stem cells that regenerate muscle throughout a person’s lifespan. The company’s lead product candidate includes ProHema, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood that is in Phase II clinical development for hematologic malignancies. It is developing pharmacologically optimized HSC therapeutics for the treatment of lysosomal storage disorders within the central nervous system; and Wnt7a Analogs that is in preclinical studies for regeneration in muscular dystrophies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.

37 Employees
Last Reported Date: 03/17/14
Founded in 2007

fate therapeutics inc (FATE) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $350.0K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $256.0K
Chief Medical Officer
Total Annual Compensation: $318.0K
Compensation as of Fiscal Year 2013.

fate therapeutics inc (FATE) Key Developments

Fate Therapeutics Submits Investigational New Drug Application for the Clinical Development of PROHEMA(R) in Inherited Metabolic Disorders

Fate Therapeutics, Inc. announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for the clinical development of PROHEMA in pediatric patients with inherited metabolic disorders undergoing hematopoietic stem cell transplantation (HSCT). Pending FDA review of the IND application, the Company plans to initiate a Phase 1b clinical trial in pediatric patients who have inherited metabolic disorders where enzyme replacement therapy is not a viable treatment option, including certain patients with central nervous system involvement. Inherited metabolic disorders include a range of genetic enzyme deficiencies that interfere with critical metabolic pathways necessary to maintain normal organ function. In many of these disorders, the enzyme deficiency leads to cellular accumulation of toxic intermediates within the brain, causing progressive neurological damage that cannot be addressed with enzyme replacement therapy. For those inherited metabolic disorders, which include over 20 lysosomal and peroxisomal storage diseases such as Hurler and Hunter syndromes, Krabbe disease and multiple leukodystrophies, allogeneic HSCT holds potential as a one-time, definitive therapy. Following allogeneic HSCT, donor-derived cells can migrate to and engraft in the brain, providing a long-term supply of an otherwise deficient enzyme to the central nervous system in a process known as cross-correction. In in-vivo murine models of allogeneic HSCT, Fate Therapeutics has demonstrated that the use of PROHEMA, as compared to unmanipulated hematopoietic stem cells (HSCs), led to a significant increase both in the engraftment of donor HSCs and in the donor-derived expression of enzyme in the brain.

Fate Therapeutics, Inc. Announces Board Changes

On June 6, 2014, Robert Nelsen, a director of Fate Therapeutics, Inc., concluded his term on the Board of Directors of the Company and all committees thereof and did not stand for re-election at the Company's 2014 Annual Meeting of Stockholders. Mr. Nelsen previously served on the Compensation Committee. The decision of Mr. Nelsen to retire from the Board of Directors did not involve any disagreement with the Company. Also on June 6, 2014, William Rastetter was appointed to the Compensation Committee of the Board of Directors to fill the vacancy created by Mr. Nelsen's retirement.

Fate Therapeutics, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 11:30 AM

Fate Therapeutics, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 11:30 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Christian Weyer, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FATE:US $6.28 USD -0.17

FATE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FATE.
View Industry Companies

Industry Analysis


Industry Average

Valuation FATE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 263.0x
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 166.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FATE THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at